TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate, TSC-101, is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA-2™ Phase 3 pivotal trial). The Company is also in early stages of developing methods for in vivo engineering to treat solid tumors. In addition, the Company is applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.
Minimum 15 minutes delayed. Source: LSEG
| Filing date | Description | Form |
|---|---|---|
| Report of unscheduled material events or corporate event | 8-K | |
| Report of unscheduled material events or corporate event | 8-K | |
| SCHEDULE 13G/A - Description | SCHEDULE 13G/A |